scispace - formally typeset
Y

Yunpeng Bai

Researcher at Purdue University

Publications -  32
Citations -  791

Yunpeng Bai is an academic researcher from Purdue University. The author has contributed to research in topics: Protein kinase B & Protein tyrosine phosphatase. The author has an hindex of 15, co-authored 32 publications receiving 617 citations. Previous affiliations of Yunpeng Bai include Indiana University & Indiana University – Purdue University Indianapolis.

Papers
More filters
Journal ArticleDOI

Therapeutic Targeting of Oncogenic Tyrosine Phosphatases

TL;DR: This review will provide topical coverage of target validation and drug discovery efforts made in targeting these oncogenic PTPs as compelling candidates for cancer therapy.
Journal ArticleDOI

Label-free biosensor: a novel phage-modified Light Addressable Potentiometric Sensor system for cancer cell monitoring.

TL;DR: A new way for detection of cancer markers and cancer cells based on phage-modified Light Addressable Potentiometric Sensor (phage-LAPS) is presented, demonstrating that the system was more applicable to Detection of cancer cell than that of cancer biomarkers.
Journal ArticleDOI

Phosphatase of regenerating liver 2 (PRL2) is essential for placental development by down-regulating PTEN (Phosphatase and Tensin Homologue Deleted on Chromosome 10) and activating Akt protein.

TL;DR: It is shown that deletion of PRL2, the most ubiquitously expressed PRL family member, leads to impaired placental development and retarded growth at both embryonic and adult stages and associates the oncogenic properties ofPRL2 with its ability to negatively regulate PTEN, thereby activating the PI3K-Akt pathway.
Journal ArticleDOI

PRL2/PTP4A2 Phosphatase Is Important for Hematopoietic Stem Cell Self‐Renewal

TL;DR: In this article, the role of protein tyrosine phosphatase 4A (PTP4A) in hematopoietic stem cell (HSC) self-renewal is defined.
Journal ArticleDOI

SHP2 phosphatase as a novel therapeutic target for melanoma treatment.

TL;DR: SHP2 levels are frequently elevated in melanoma, and high SHP2 expression is significantly associated with more metastatic phenotype and poorer prognosis, and SHP 2 inhibitors are suggested as potential novel therapeutic agents for melanoma treatment.